Navigation Links
PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes
Date:3/5/2012

INCLINE VILLAGE, Nev., March 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its:

  • 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 159.098 shares of common stock per $1,000 principal amount or approximately $6.29 per share, effective March 8, 2012;
  • 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes) is 139.2165 shares of common stock per $1,000 principal amount or approximately $7.18 per share, effective March 5, 2012; and
  • 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes) is 159.098 shares of common stock per $1,000 principal amount or approximately $6.29 per share, effective March 5, 2012.

 

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

The conversion rates for the notes are adjusted in connection with the regular quarterly dividend of $0.15 to be paid on March 14, 2012, to all stockholders who own shares of PDL on March 7, 2012, the record date.

February 2015 Notes

The conversion rate for the February 2015 Notes was previously 155.396 shares of common stock per $1,000 principal amount of the February 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of March 5, 2012, for the cash dividend, and the denominator of which is such average closing price minus the per share dividend amount.

May 2015 Notes

The conversion rate for the May 2015 Notes was previously 135.9607 shares of common stock per $1,000 principal amount of the May 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the 10 consecutive trading days immediately preceding the ex-dividend date of March 5, 2012, for the cash dividend, and the denominator of which is such average closing price minus the per share dividend amount.

Series 2012 Notes

The conversion rate for the Series Notes was previously 155.396 shares of common stock per $1,000 principal amount of the Series 2012 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of March 5, 2012, for the cash dividend, and the denominator of which is such average closing price minus the per share dividend amount.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

The foregoing statements regarding PDL's intentions with respect to the cash dividend payment described above constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Important factors that could impair the value of the Company's royalty assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2011 Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2012. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medtrack One View - A New More Powerful Biopharmaceutical Intelligence Tool Is Now Available
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
4. Innovative School of BioPharmacy to Open in Fall 2014
5. The Centers for Disease Control & Prevention Signs Vaccine Warehouse and Distribution Contract with Sentry BioPharma Services
6. PDL BioPharma to Announce Fourth Quarter and Full Year 2011 Financial Results on February 23, 2012
7. Top 200 Biopharmaceuticals Industry Report (Global)
8. Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
9. PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
10. Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement
11. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services ... The announcement was made by Bill Monast , ... Hartley and Nathan Feltman , executives with ... Healthcare Services, LLC. This acquisition helps ... provider of technology enabled durable medical equipment (DME) solutions ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device company that ... pain, today reported financial results for the three months and ... Accomplishment & Highlights: Achieved revenue of $228.5 ... as reported, over the prior year U.S. revenue ... the prior year International revenue of $55.2 ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Curemark, LLC announced ... and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at ... already enrolling children across the United States. , “There are currently no approved ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered ... exercise regime, the author was able to successfully recover. In “ Origin & Insertion ... for various sources on the principals of massage, anatomy , trigger points ...
Breaking Medicine News(10 mins):